|
Nov 9
|
Gilead Sciences: Research Scholars Program Scientists Advancing HIV Research
|
|
Nov 9
|
Top 20 Drug Companies in the US by Revenue
|
|
Nov 9
|
Gilead Sciences to Present at Upcoming Investor Conferences
|
|
Nov 8
|
Gilead Tumbles After An Unpredictable Element Drove Its Third-Quarter Beat
|
|
Nov 8
|
Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2023 Earnings Call Transcript
|
|
Nov 8
|
Gilead (GILD) Q3 Earnings Beat, Trodelvy Fuels Oncology Sales
|
|
Nov 8
|
Midday movers: Warner Bros Discovery, Eli Lilly, Robinhood and more
|
|
Nov 8
|
Q3 2023 Gilead Sciences Inc Earnings Call
|
|
Nov 8
|
Gilead reports better-than-expected earnings amid strong cancer drug sales
|
|
Nov 8
|
The Gilead Sciences Inc (GILD) Company: A Short SWOT Analysis
|
|
Nov 8
|
Gilead Sciences (GILD) Q3 2023 Earnings Call Transcript
|
|
Nov 7
|
Compared to Estimates, Gilead (GILD) Q3 Earnings: A Look at Key Metrics
|
|
Nov 7
|
Gilead Sciences (GILD) Tops Q3 Earnings and Revenue Estimates
|
|
Nov 7
|
UPDATE 1-Gilead quarterly results beat Street estimates as lower taxes boost profit
|
|
Nov 7
|
Gilead quarterly results beat Street estimates as lower taxes boost profit
|
|
Nov 7
|
Gilead Sciences Announces Third Quarter 2023 Financial Results
|
|
Nov 7
|
Gilead quarterly results beat Street estimates as profit up on lower taxes
|
|
Nov 7
|
Gilead Sciences: Advancing Global Health Equity in Tropical Regions
|
|
Nov 6
|
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers
|
|
Nov 6
|
Institutional investors must be pleased after a 4.9% gain last week that adds to Gilead Sciences, Inc.'s (NASDAQ:GILD) one-year returns
|